ARCHIVES

Promising Results For Glivec In CML Continue, FDA Grants Priority Review

This article is from The Cancer Letter archive.

Vol. 24 No. 4 | April 27, 2001

Download PDF Visit The Full Archive

Related Articles

NCI Exceeded Mandate In Study Of Legislators, Rep. Porter Says

August 11, 1995

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012

Duke Retraction May Alter IOM Investigation; Review Panel Membership Announced

November 5, 2010

CCOP Wins Vote Of Confidence From NCI Advisors

November 12, 2010

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

March 10, 1989

In Brief: Durant To Retire From ASCO In A Year; Led Society Through Management Change

July 24, 1998